Literature DB >> 11922737

Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus.

Masahiro Shimomura1, Satohiro Masuda, Hideyuki Saito, Seisuke Sakamoto, Shinji Uemoto, Koichi Tanaka, Ken-ichi Inui.   

Abstract

BACKGROUND: The immunosuppressant tacrolimus shows poor and variable bioavailability following oral administration in clinical use. Recently, the hepatic and intestinal metabolisms, or first-pass effect, of tacrolimus have been suggested to be responsible for its bioavailability. In the present study, we investigated the respective contribution of the jejunum and ileum to the first-pass effect of tacrolimus in rats.
METHODS: The metabolism of tacrolimus in everted sacs of the duodenum, jejunum, and ileum was examined. Tacrolimus was administered intravenously or intraintestinally to sham-operated, jejunum-resected, or ileum-resected rats. Blood samples were collected over a 240-min period, and whole-blood tacrolimus concentrations were measured by semiautomated microparticle enzyme immunoassay. The pharmacokinetic parameters of tacrolimus in each group were estimated.
RESULTS: The metabolic activity of tacrolimus appeared to be the highest in the everted sacs of the duodenum. The bioavailability of tacrolimus in the jejunum- or ileum-resected rats was higher than that in sham-operated controls. On the other hand, the time to peak concentration in the jejunum-resected rats was about twofold slower than those in ileum-resected and sham-operated rats.
CONCLUSIONS: These results suggested that the first-pass effect of tacrolimus in the small intestine shows regional differences and the extraction of tacrolimus in the small intestine consists of the amount of extraction in the jejunum and ileum. In addition, the ileum rather than the jejunum as a graft of segmental small bowel transplantation would be useful to avoid the adverse effects of tacrolimus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922737     DOI: 10.1006/jsre.2002.6359

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus.

Authors:  Vivek Borhade; Hema Nair; Darshana Hegde
Journal:  AAPS PharmSciTech       Date:  2008-01-04       Impact factor: 3.246

2.  Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.

Authors:  Christin C Rogers; Rita R Alloway; J Wesley Alexander; Michael Cardi; Jennifer Trofe; Alexander A Vinks
Journal:  Clin Transplant       Date:  2008 May-Jun       Impact factor: 2.863

3.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients.

Authors:  Tadashi Sofue; Masashi Inui; Hideyasu Kiyomoto; Kumiko Moriwaki; Taiga Hara; Kazunori Yamaguchi; Noriyasu Fukuoka; Kazuko Banno; Akira Nishiyama; Yoshiyuki Kakehi; Masakazu Kohno
Journal:  Clin Exp Nephrol       Date:  2012-12-27       Impact factor: 2.801

Review 5.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

6.  Temporary Parenteral Tacrolimus Requirement due to Unexplained Low Through Levels in a Liver Transplant Patient with Short Bowel Syndrome.

Authors:  V Ince; F Ozdemir; B Isik; M Yilmaz; C Kayaalp; S Yilmaz
Journal:  Int J Organ Transplant Med       Date:  2014
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.